Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00762476 · ClinicalTrials.gov registry record · Phase 2

Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses

A Phase 2 study of Common Cold, sponsored by The Dial Corporation.

Completed
Registry status
Phase 2
Development phase
411
Enrollment target
2
Study locations

NCT00762476 is a Phase 2 study of Common Cold that has completed, run by The Dial Corporation. The registered enrollment target is 411 participants, above the 352-participant average among 5 other Common Cold trials with a reported enrollment target (17% higher). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00762476, a Phase 2 study of Common Cold, has completed, sponsored by The Dial Corporation.

COMPLETED
Registry status
Phase 2
Development phase
411 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy of 3804-250A in the prevention of the common cold. The study will also evaluate whether 3804-250A prevents rhinovirus infection, a virus that causes many common colds.

Conditions Studied

Interventions

  • DRUG 3804-250A
  • DRUG 3804-291

Study Locations (2)

New Jersey

  • TKL Research, Inc. - Paramus

Virginia

  • University of Virginia School of Medicine - Charlottesville

Trial Details

FieldValue
Enrollment Target 411 participants
Start Date 2008-08
Est. Completion 2008-11
Phase Phase 2

Sponsor

The Dial Corporation

1 total trials

What the Registry Record Tells You About NCT00762476

The ClinicalTrials.gov registry entry for NCT00762476 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 411 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 352-participant average among 5 other Common Cold trials with a reported enrollment target (17% higher). The listed sponsor is The Dial Corporation, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Common Cold appearing as the primary indexed condition, and to 2 interventions - of which 3804-250A is the first listed.

NCT00762476 reports 2 study locations spanning 2 distinct geographic areas - top geographies include New Jersey, Virginia.

Frequently Asked Questions

What is clinical trial NCT00762476 about?

NCT00762476 is a clinical study titled "Efficacy Trial of 3804-250A in the Prevention of Cold Illnesses". The purpose of this study is to evaluate the efficacy of 3804-250A in the prevention of the common cold. The study will also evaluate whether 3804-250A prevents rhinovirus infection, a virus that causes many common colds.

What is the current status of trial NCT00762476?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 411 participants. The study started on 2008-08. Estimated completion is 2008-11.

What conditions does trial NCT00762476 study?

This clinical trial studies the following conditions: Common Cold.

What interventions are being tested in trial NCT00762476?

The interventions under investigation include: 3804-250A (DRUG), 3804-291 (DRUG).

Who is sponsoring clinical trial NCT00762476?

This trial is sponsored by The Dial Corporation, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00762476 being conducted?

This trial has 2 study locations across New Jersey, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Common Cold

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.